ESSENCE (Completed)
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia
- Medicine
- Olezarsen
- Population
- ASCVD
- Phase
- III
- Starting year
- 2022